Sana Biotechnology Inc Cash Flow Conversion Efficiency
Sana Biotechnology Inc cash flow conversion efficiency. Based on the latest financial reports, Sana Biotechnology Inc (SANA) has a cash flow conversion efficiency ratio of -0.212x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.79 Million) by net assets ($154.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sana Biotechnology Inc (2018–2025)
Cash flow conversion efficiency of Sana Biotechnology Inc from 2018 to 2025. This chart illustrates how Sana Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SANA stock price for real-time trading data and today's change.
Sana Biotechnology Inc Cash Flow Conversion Ratio Explained
Sana Biotechnology Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sana Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sana Biotechnology Inc ranked by their cash flow conversion efficiency. Also see Sana Biotechnology Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Latham Group Inc
NASDAQ:SWIM
|
0.130x |
|
Shandong Mining Machinery Group Co Ltd
SHE:002526
|
0.049x |
|
Hang Xiao Steel Structure Co Ltd
SHG:600477
|
0.025x |
|
Shijiazhuang Kelin Elec Co
SHG:603050
|
0.182x |
|
Greenworks (Jiangsu) Co. Ltd. A
SHE:301260
|
N/A |
|
Shenzhen JT Automation Equipment Co Ltd
SHE:300400
|
0.060x |
|
Jiangxi Hungpai New Material Co Ltd
SHG:605366
|
0.014x |
|
Kelsian Group Ltd
AU:KLS
|
0.087x |
Annual Cash Flow Conversion Efficiency for Sana Biotechnology Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Sana Biotechnology Inc from 2018 to 2025. Review SANA free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $160.88 Million | $-143.83 Million | -0.894x | -0.36% |
| 2024-12-31 | $250.50 Million | $-223.15 Million | -0.891x | -1.00% |
| 2023-12-31 | $287.51 Million | $-253.58 Million | -0.882x | -51.84% |
| 2022-12-31 | $499.31 Million | $-290.05 Million | -0.581x | -68.56% |
| 2021-12-31 | $728.50 Million | $-251.05 Million | -0.345x | -205.19% |
| 2020-12-31 | $-421.18 Million | $-137.98 Million | 0.328x | -45.39% |
| 2019-12-31 | $-142.54 Million | $-85.50 Million | 0.600x | -41.38% |
| 2018-12-31 | $-13.19 Million | $-13.49 Million | 1.023x | -- |
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more